Researcher Tweaks T-Cells for Tumors

Posted: Updated:
Nallathamby and his team are developing a double-sided nanoparticle. Nallathamby and his team are developing a double-sided nanoparticle.

A new cutting-edge cancer treatment called CAR T-cell therapy—which requires only a single treatment—is curing patients with certain lymphomas and blood cancers, but researchers are struggling to translate the treatment for solid tumors. National Breast Cancer Awareness Month is coming to a close, but University of Notre Dame researcher Dr. Prakash Nallathamby is holding steadfast to his goal of unleashing the power of CAR T-cells for breast cancer tumors—a disease that has taken two members of his family.

“So it’s personal for me,” says Nallathamby, whose grandmother and aunt died battling breast cancer. “That personal side of it has had a huge impact, and it is a great motivator to see what more we can do to fight this disease.”

CAR T-cell therapy, designed for patients who don’t respond to conventional therapy, has been administered to just two Hoosier patients. The therapy involves taking a patient’s T-cells (a type of immune system cell) and changing them in the laboratory, so they’ll attack cancer cells when injected back into the patient.

Experts call it a cure and the next chapter of cancer treatment, “but the only setback so far seems to be that it’s only applicable for different lymphomas and blood cancers,” says Nallathamby, “so if there’s any way we could use this for solid [tumors], that’d be great.”

Nallathamby, a research assistant professor of aerospace and mechanical engineering and affiliated member of NDnano, has made it his mission to translate T-cell therapy for solid tumors and is first taking aim at breast cancer.

“Right now, when CAR T-cells are used against solid tumors, there have been some really bad results with regard to [the T-cells] being so efficient that the whole tumor bursts, and it leads to something called tumor lysis syndrome [in which large amounts of killed tumor cells release their contents into the bloodstream],” says Nallathamby. “Or [T-cells] target healthy tissue, and they can’t be switched off. If [T-cells] attack the heart or lungs, it kills the patient.”

Nallathamby’s strategy centers on a unique nanoparticle that his team has designed to take control of the powerful T-cells. The nanoparticle’s key feature is its double-sided structure; one end is designed to bind to the surface of the tumor, and the other has a special receptor that captures the CAR T-cells, ensuring the T-cells will only attach to the nanoparticle, therefore, attacking the tumor and not healthy tissue.

Nallathamby is using a special category of T-cells, called universal CAR T-cells (uCAR T-cells). These are commercially-available T-cells, instead of the conventional T-cells that need to be obtained from the patient. Nallathamby says current CAR T-cell treatment requires 20 to 30 days, but because universal T-cells are readily available, they can be administered within two to three days.

Finally, Nallathamby says a nano activator is injected, providing even more control over the T-cells. The nano activator “turns on” the uCAR T-cells and the dosage amount dictates their killing power, so they don’t attack the tumor too quickly and trigger tumor lysis syndrome.

Importantly, as the activator is depleted, the powerful uCAR T-cells are “turned off.” The specially-designed nanoparticles will also release their grip on the tumor after three to four days and are naturally flushed out of the body. This double layer of protection ensures the T-cells don’t cause any negative “off target” effects in the body.

While still in the early stages of development, Nallathamby believes the strategy will also translate well for ovarian and prostate cancer. Nallathamby says CAR T-cells—while extremely powerful—must also be harnessed to avoid the negative effects of such might. He’s confident managing CAR T-cells’ use in tumors with his specially-designed nanoparticles could unlock the treatment for many more cancers and patients.

In addition to his personal connection to breast cancer, Nallathamby says he chose the disease because it’s a robust area of research.
Nallathamby says advances in immunotherapy, such as CAR T-cell treatment, are also important because patients can maintain a more normal lifestyle.
  • Perspectives

    • Richardson is a practice lead with Centric Consulting.

      How to Create Consistent and Positive Customer Experiences with Your Brand

      Everyone knows that keeping the consumer happy is the first priority. The importance of considering the customer’s experience in all areas of engaging with your business, not just customer service is becoming even more clear. I’m seeing an increasing number of my peers in the marketing world take ownership of the customer experience with their brands. As a result, we’re all learning how to borrow and...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • (image courtesy of The Times of Northwest Indiana)

      U.S. Steel Updates Layoff Notice to State

      Pittsburgh-based U.S. Steel Corp. (NYSE: X) has updated the State of Indiana regarding its previously announced layoffs at the East Chicago Tin Mill. The company says 314, rather than 307, workers will be displaced when the mill is idled this fall. 

    • Red Star announced plans to expand and add 18 jobs.

      Larwill Medical Device Maker to Expand, Add Jobs

      A Whitley County-based medical device maker has announced plans to expand its facility in Larwill which should mean new jobs. Red Star Contract Manufacturing Inc. says it will invest $1.6 million in real estate improvements and additional equipment and will create 18 new jobs by 2022. 

    • Regal Beloit is closing in Valparaiso. (photo courtesy; The Times of Northwest Indiana)

      Valpo Bearings Plant to Close, Eliminating 160+ Jobs

      Wisconsin-based Regal Beloit Corp. and the union representing workers have reached an agreement about the closing of a helicopter bearing factory in Valparaiso. According to our partners at The Times of Northwest Indiana, the decision will cost between 160 to 170 workers their jobs. 

    • (WISH-TV Photo)

      Clif Bar Expands Indy Bakery

      California-based Clif Bar & Co. has completed a $10 million expansion of its commercial bakery in Indianapolis. The company says the project involved a more sustainable redesign of the facility for its employee-owners with a greater focus on energy efficiency.

    • Bob Stutz

      New Role For Salesforce Exec

      After three years on the job, Salesforce Marketing Cloud Chief Executive Officer Bob Stutz is moving into a new role. Stutz, who will remain in Indianapolis, is now executive vice president of strategic partners at Salesforce (NYSE: CRM).  Since arriving in Indianapolis, Stutz has overseen the establishment of the company’s regional headquarters in downtown Indianapolis, which included the Salesforce name being placed atop the state’s tallest building.